Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotemax Gel for Restasis Initiation in Dry Eye
NCT02028312Phase 4
Key facts
- Status
- Withdrawn
- Start
- Jan 2014
- Primary completion
- Feb 2016
- Countries
- 1
- Conditions
- dry eye disease (DED)
01
Overview
Phase 4, randomised, single-blind trial of loteprednol etabonate in dry eye disease (DED). Primary endpoint: Fluorescein corneal staining at 60 days. Planned start Jan 2014; status: withdrawn.
02
Design
- Study design
- RandomizedSingle-blind
03
Who it enrols
Adults aged 21-80 with dry eye disease, excluding those with recent ocular surgery, contact lens use, or prior recent use of topical steroids or Restasis.
04
Endpoints
Primary
Fluorescein corneal staining
Beyond the preview
Go deeper on NCT02028312.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028312.